These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 23635804)

  • 1. SCN5A promoter haplotype affects the therapeutic range for serum flecainide concentration in Asian patients.
    Doki K; Homma M; Kuga K; Aonuma K; Kohda Y
    Pharmacogenet Genomics; 2013 Jul; 23(7):349-54. PubMed ID: 23635804
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimal sampling time and clinical implication of the SCN5A promoter haplotype in propafenone therapeutic drug monitoring.
    Doki K; Shirayama Y; Sekiguchi Y; Aonuma K; Kohda Y; Homma M
    Eur J Clin Pharmacol; 2018 Oct; 74(10):1273-1279. PubMed ID: 30116829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Use of Pharmacogenetic Information for Therapeutic Drug Monitoring of an Antiarrhythmic Drug].
    Doki K
    Yakugaku Zasshi; 2018; 138(9):1145-1150. PubMed ID: 30175758
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gender-associated differences in pharmacokinetics and anti-arrhythmic effects of flecainide in Japanese patients with supraventricular tachyarrhythmia.
    Doki K; Homma M; Kuga K; Aonuma K; Sakai S; Yamaguchi I; Kohda Y
    Eur J Clin Pharmacol; 2007 Oct; 63(10):951-7. PubMed ID: 17665182
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Common sodium channel promoter haplotype in asian subjects underlies variability in cardiac conduction.
    Bezzina CR; Shimizu W; Yang P; Koopmann TT; Tanck MW; Miyamoto Y; Kamakura S; Roden DM; Wilde AA
    Circulation; 2006 Jan; 113(3):338-44. PubMed ID: 16415376
    [TBL] [Abstract][Full Text] [Related]  

  • 6. β1-Adrenergic receptor Arg389Gly polymorphism affects the antiarrhythmic efficacy of flecainide in patients with coadministration of β-blockers.
    Doki K; Sekiguchi Y; Kuga K; Aonuma K; Homma M
    Pharmacogenet Genomics; 2016 Oct; 26(10):481-5. PubMed ID: 27500822
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Normalization of ventricular repolarization with flecainide in long QT syndrome patients with SCN5A:DeltaKPQ mutation.
    Windle JR; Geletka RC; Moss AJ; Zareba W; Atkins DL
    Ann Noninvasive Electrocardiol; 2001 Apr; 6(2):153-8. PubMed ID: 11333173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Flecainide acetate: concentration-response relationships for antiarrhythmic and electrocardiographic effects.
    Boriani G; Capucci A; Strocchi E; Calliva R; Santarelli A; Biffi M; Magnani B
    Int J Clin Pharmacol Res; 1993; 13(4):211-9. PubMed ID: 8150547
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of flecainide in patients with new SCN5A mutation: mutation-specific therapy for long-QT syndrome?
    Benhorin J; Taub R; Goldmit M; Kerem B; Kass RS; Windman I; Medina A
    Circulation; 2000 Apr; 101(14):1698-706. PubMed ID: 10758053
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic-pharmacodynamic modeling of QRS-prolongation by flecainide: heart rate-dependent effects during sinus rhythm in conscious telemetered dogs.
    Sällström J; Al-Saffar A; Pehrson R
    J Pharmacol Toxicol Methods; 2014; 69(1):24-9. PubMed ID: 24140388
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiarrhythmic Action of Flecainide in Polymorphic Ventricular Arrhythmias Caused by a Gain-of-Function Mutation in the Nav 1.5 Sodium Channel.
    Amarouch MY; Swan H; Leinonen J; Marjamaa A; Lahtinen AM; Kontula K; Toivonen L; Widen E; Abriel H
    Ann Noninvasive Electrocardiol; 2016 Jul; 21(4):343-51. PubMed ID: 26965448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful treatment of supraventricular tachycardia with flecainide acetate: a case report.
    Amano K; Harada Y; Shoda T; Nishijima M; Hiraishi S
    Fetal Diagn Ther; 1997; 12(6):328-31. PubMed ID: 9475360
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of sodium channel blockers on ST segment, QRS duration, and corrected QT interval in patients with Brugada syndrome.
    Shimizu W; Antzelevitch C; Suyama K; Kurita T; Taguchi A; Aihara N; Takaki H; Sunagawa K; Kamakura S
    J Cardiovasc Electrophysiol; 2000 Dec; 11(12):1320-9. PubMed ID: 11196553
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term flecainide therapy in type 3 long QT syndrome.
    Chorin E; Taub R; Medina A; Flint N; Viskin S; Benhorin J
    Europace; 2018 Feb; 20(2):370-376. PubMed ID: 28339995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multifocal Ectopic Purkinje-Related Premature Contractions Syndrome in R222Q-SCN5A Gene Mutation Carriers Treated With Flecainide.
    Basile P; Napoli G; Anaclerio M; Forleo C; Guaricci AI
    JACC Clin Electrophysiol; 2022 Oct; 8(10):1334-1336. PubMed ID: 36266013
    [No Abstract]   [Full Text] [Related]  

  • 16. Assessment of serum flecainide trough levels in patients with tachyarrhythmia.
    Homma M; Kuga K; Doki K; Katori K; Yamaguchi I; Sugibayashi K; Kohda Y
    J Pharm Pharmacol; 2005 Jan; 57(1):47-51. PubMed ID: 15638992
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Translation of flecainide- and mexiletine-induced cardiac sodium channel inhibition and ventricular conduction slowing from nonclinical models to clinical.
    Heath BM; Cui Y; Worton S; Lawton B; Ward G; Ballini E; Doe CP; Ellis C; Patel BA; McMahon NC
    J Pharmacol Toxicol Methods; 2011; 63(3):258-68. PubMed ID: 21194571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Flecainide, a therapeutic option in a patient with long QT syndrome type 3 caused by the heterozygous V411M mutation in the SCN5A gene.
    Carrasco JI; Izquierdo I; Medina P; Arnau MÁ; Salvador A; Zorio E
    Rev Esp Cardiol (Engl Ed); 2012 Nov; 65(11):1058-9. PubMed ID: 22721569
    [No Abstract]   [Full Text] [Related]  

  • 19. Effects of flecainide and quinidine on arrhythmogenic properties of Scn5a+/Delta murine hearts modelling long QT syndrome 3.
    Stokoe KS; Thomas G; Goddard CA; Colledge WH; Grace AA; Huang CL
    J Physiol; 2007 Jan; 578(Pt 1):69-84. PubMed ID: 17023504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Haemolysis alters plasma flecainide levels in newborn infants.
    Vento M; Tudela BF; Escrig R; Sáenz P; Sánchez A; Cano A
    Acta Paediatr; 2007 Mar; 96(3):466-8. PubMed ID: 17407483
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.